Combination Hepatitis C/HIV Therapy Approved in Europe
Schering-Plough said that the European Commission (EC) has approved combination therapy with its drugs Peg-Intron (peginterferon alfa-2b, 1.5 mcg/kg once weekly) and Rebetol (ribavirin, 800–1,200 mg daily) to treat previously untreated adult patients with chronic hepatitis C who are coinfected with clinically stable HIV.
Approximately 40 percent of the estimated 2.5 million people living with HIV in Europe are coinfected with the hepatitis C virus (HCV), according to the World Health Organization. The EC’s approval of this combination therapy means that the company can now market it with unified labeling anywhere in the 27 European Union (EU) member states as well as in Iceland and Norway.
The combination of the two drugs was approved in the EU in March 2001 for treating adult patients with chronic HCV alone.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May